-
公开(公告)号：US09868724B2
公开(公告)日：2018-01-16
申请号：US15314107
申请日：2015-05-26
Inventor： Hui Lei , Xin Ma , Feng Ren , Xichen Lin , Robert W. Marquis, Jr.
IPC: C07D417/14 , C07D405/14 , C07D405/06 , C07D241/04
CPC classification number: C07D405/06 , C07D241/04 , C07D405/14 , C07D417/14
Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
-
公开(公告)号：US10858367B2
公开(公告)日：2020-12-08
申请号：US16480797
申请日：2018-01-23
Inventor： Xiao Ding , Feng Ren , Yingxia Sang , Weiqiang Xing , Yang Zhan , Baowei Zhao
IPC: C07D491/08 , C07D401/14
Abstract: Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
-
公开(公告)号：US11034696B2
公开(公告)日：2021-06-15
申请号：US16480762
申请日：2018-01-23
Inventor： Feng Ren , Yingxia Sang , Weiqiang Xing , Yang Zhan , Baowei Zhao
IPC: C07D487/04 , C07D407/14 , C07D413/14 , C07D487/10 , C07D491/048 , C07D498/04 , C07D498/10 , A61P25/16 , A61P25/28 , A61P25/14
Abstract: Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
-
Patent Agency Ranking
4.发明授权公开(公告)号：US10336719B2
公开(公告)日：2019-07-02
申请号：US16129867
申请日：2018-09-13
Inventor： Weichun Chen , Ebere F Igboko , Xichen Lin , Hongfu Lu , Feng Ren , Paul Bryan Wren , Zhongmiao Xu , Ting Yang , Lindong Zhu
IPC: C07D307/18 , C07D241/04 , C07D309/08 , C07C317/50 , C07C317/42 , C07C311/47 , C07D305/06 , C07D213/34 , C07D295/135 , C07D211/54 , C07D207/10 , C07D487/04 , C07D471/04 , C07D239/26 , C07D233/64
Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
-
5.发明授权公开(公告)号：US10106515B2
公开(公告)日：2018-10-23
申请号：US15314124
申请日：2015-05-27
Inventor： Weichun Chen , Ebere F Igboko , Xichen Lin , Hongfu Lu , Feng Ren , Paul Bryan Wren , Zhongmiao Xu , Ting Yang , Lingdong Zhu
IPC: C07D307/18 , C07D241/04
Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
-
公开(公告)号：US10975081B2
公开(公告)日：2021-04-13
申请号：US15746817
申请日：2016-07-22
Inventor： Xiao Ding , Yun Jin , Qian Liu , Feng Ren , Yingxia Sang , Luigi Piero Stasi , Zehong Wan , Hailong Wang , Weiqiang Xing , Yang Zhan , Baowei Zhao
IPC: C07D487/04 , A61P25/28 , A61P25/16 , A61K31/5377
Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
-
公开(公告)号：US20190010135A1
公开(公告)日：2019-01-10
申请号：US16129867
申请日：2018-09-13
Inventor： Weichun Chen , Ebere F. Igboko , Xichen Lin , Hongfu Lu , Feng Ren , Paul Bryan Wren , Zhongmiao Xu , Ting Yang , Lindong Zhu
IPC: C07D307/18 , C07D241/04 , C07D309/08 , C07C317/50 , C07C317/42 , C07C311/47 , C07D305/06 , C07D213/34 , C07D295/135 , C07D211/54 , C07D207/10 , C07D487/04 , C07D471/04 , C07D239/26 , C07D233/64
CPC classification number: C07D307/18 , C07C311/47 , C07C317/42 , C07C317/50 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07D207/10 , C07D211/54 , C07D213/34 , C07D233/64 , C07D239/26 , C07D241/04 , C07D295/135 , C07D305/06 , C07D309/08 , C07D471/04 , C07D487/04
Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
-
公开(公告)号：US09902715B2
公开(公告)日：2018-02-27
申请号：US15314106
申请日：2015-05-26
IPC: C07D403/12 , C07D403/06 , C07D401/12 , C07D403/14 , C07D401/06 , C07D401/14 , C07D241/04
CPC classification number: C07D403/14 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12
Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.021 seconds)
